Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively. - Submission of an Investigational New Drug...
Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation
Strategic collaboration establishes a framework to integrate automated experimentation and advanced chemistry workflows to accelerate research and discovery in Life Science and Electronics SINGAPORE and SHANGHAI, Jan. 20, 2026 /PRNewswire/ -- Merck, a leading science and technology company, and ChemLex, a Singapore-headquartered innovation company pioneering AI-driven automated chemical synthesis, today announced the signing of a Memorandum of Understanding (MOU)...
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ technology, for the development and commercialization of a subcutaneous formulation...
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion),...
cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments
SYDNEY, Jan. 20, 2026 /PRNewswire/ -- Cerebral Palsy Alliance, The University of Sydney, and CSIRO, Australia's national science agency, have commissioned Miroma Project Factory to deliver a groundbreaking mobile app that helps people with cerebral palsy (CP), their carers, and clinicians understand and navigate evidence-based treatments with confidence. Developed by Miroma Project Factory in...
Beauty Farm Issues Positive Profit Alert for 2025
HONG KONG, Jan. 20, 2026 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services providers in China, issued a positive profit alert for the year ended December 31, 2025. As disclosed, the Company anticipates revenue of not less than RMB 3.0 billion for the...
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women’s and Children’s Healthcare in India
SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- Novo Holdings, a leading global healthcare and life sciences investor, today announced that it has made an investment in Surya Hospitals, the largest private women's and children's specialty hospital chain in Western India. The investment is for a significant minority stake and underscores Novo Holdings' continued commitment to building scaled, high-quality healthcare platforms...
AIM Vaccine’s 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the National Medical Products Administration. This marks a further enrichment and enhancement of AIM's research and development...
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), Telix's...
Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability
TOKYO, Jan. 20, 2026 /PRNewswire/ -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability within the medical field. Peter Nobel and Mari Sakai ...
